Medical device firm Boston Scientific has secured approval from the US Food and Drug Administration (FDA) for its Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, and magnetic resonance (MR) conditional labelling for all previously implanted Emblem S-ICD Systems.

The Emblem S-ICD Systems serve as treatment options for patients vulnerable to sudden cardiac arrest (SCA), which leaves the heart and vasculature untouched, decreasing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators.

Boston Scientific rhythm management chief medical officer Kenneth Stein said: "Now with FDA approval, patients receiving the Emblem MRI S-ICD System, as well as patients who previously were implanted with an Emblem S-ICD System, have reassurance they can safely undergo MR scans while remaining protected from cardiac arrest."

"The Smart Pass technology will help ensure patients receive therapy from the device when necessary by improving the Insight Algorithm."

The Smart Pass technology will help ensure patients receive therapy from the device when necessary by improving the Insight Algorithm, which identifies and categorises a heart rhythm for effective arrhythmia treatment.

This feature can be incorporated into the previously implanted Emblem S-ICD Systems through a software update.

The AF monitor of the Emblem MRI S-ICD System is a new detection tool developed to notify physicians after identifying AF to facilitate a more informed treatment decision for their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Boston Scientific has also obtained the FDA approval for its ImageReady MR-Conditional Pacing System featuring Accolade MRI and Essentio MRI pacemakers as well as Ingevity MRI pacing leads to treat bradycardia.